



Date: 30th May, 2025

To,
BSE Ltd.,
Listing Department,
Phiroze Jeejeebhoy Towers,
Dalal Street - Fort,
Mumbai – 400 001

Scrip Code: 539730

Dear Sir/ Madam,

Sub.: Press Release

Please find enclosed press release titled “**Fredun Pharmaceuticals Reports Robust Q4 & FY25 Performance**” issued by Fredun Pharmaceuticals Limited.

Thanking you,

Yours truly,

For Fredun Pharmaceuticals Limited

Fredun Medhora
Managing Director

Encl.

Fredun Pharmaceuticals Reports Robust Q4 & FY25 Performance

Total Income

30.7% YoY | 41.8% YoY

Rs. 456.3 Cr in FY25 | Rs. 167.4 in Q4FY25

EBITDA

41.6% YoY | 56.2% YoY

Rs. 55.1 Cr in FY25 | Rs. 17.4 in Q4FY25

PAT

33.2% YoY | 39.7% YoY

Rs. 20.8 Cr in FY25 | Rs. 7.1 in Q4FY25

Mumbai, India, 30 May 2025: Fredun Pharmaceuticals Limited (BSE: 539730), a leading provider of pharmaceuticals and innovative healthcare solutions for human and veterinary applications, announced their financial results for the **quarter and year ended March 31, 2025.**

Financial Highlights:

Particulars (Rs. Cr)	Q4FY25	Q4FY24	YoY (%)	FY25	FY24	YoY (%)
Total Income	167.4	118.0	41.8%	456.3	349.1	30.7%
EBITDA	17.4	11.2	56.2%	55.1	38.9	41.6%
EBITDA Margin (%)	10.4%	9.5%		12.1%	11.1%	
PAT	7.1	5.1	39.7%	20.8	15.6	33.2%
PAT Margin (%)	4.2%	4.3%		4.6%	4.5%	

Key Financial Highlights for Q4 FY25:

- **Total Income** stood at Rs. 167.4 Cr as against Rs. 118.0 Cr in Q4FY24; a growth of 41.8% YoY
- **EBITDA** at Rs. 17.4 Cr as against Rs. 11.2 Cr in Q4FY24 a growth of 56.2% YoY; EBITDA Margin at 10.4%
- **Profit after Tax** stood at Rs. 7.1 Cr in Q4FY25 as against Rs. 5.1 Cr, healthy growth of 39.7% YoY

Key Financial Highlights for FY25:

- **Total Income** stood at Rs. 456.3 Cr a growth of 30.7% YoY against Rs. 349.1 Cr reported in FY24
- **EBITDA** at Rs. 55.1 Cr against Rs. 38.9 Cr a strong growth of 41.6% YoY
- The EBITDA margin for FY25 was at 12.1% against 11.1% in FY24
- **Profit After Tax** stood at Rs. 20.8 Cr against Rs. 15.6 Cr a robust growth of 33.2% YoY

Key Business Updates During Q4FY25:

- **Foray into Large Animal Veterinary Products:** Foray into the large animal veterinary segment with the launch of its FREOSSI Large Animals brand. This expansion introduces targeted products, Freossi Tone+ and Freossi Power, specifically designed to address critical health challenges faced by livestock owners. Developed with the expertise of veterinary professionals, these scientifically formulated products aim to improve lactation cycles, enhance milk quality, and alleviate joint stiffness in large animals.

- **International Expansion of Freossi Petcare Division:** Launched Freossi pet care division in Sri Lanka, marking its first international foray. The introduction of nine premium-quality pet care products, along with a pipeline of over 20 additional offerings, highlights the company's commitment to enhancing the health and well-being of pets globally. The launch was inaugurated by esteemed veterinary professionals, highlighting the collaboration with experts in the field. Freossi aims to provide meticulously formulated products that cater to the diverse needs of pets and their owners, reinforcing its mission to deliver high-quality pet food and grooming solutions.
- **Tender Award from TNMSC for Generic Pharma Products:** Secured a significant tender from the Tamil Nadu Medical Services Corporation (TNMSC) for the supply of generic medicines, valued between Rs. 150 million and Rs. 180 million. This tender reflects the company's commitment to providing high-quality and affordable healthcare solutions to the community.
- **Order Book Updates:** Order book of around Rs. 213 crores which is highest ever compared to previous years

Commenting on the Development, Mr. Fredun Medhora, Managing Director, said: "This year has been a transformative period for Fredun Pharmaceuticals, characterized by expansion and strategic initiatives. Our commitment to enhancing our product offerings and establishing a robust Non-Pharma business is paving the way for increased profitability and strong growth. As we navigate through this dynamic landscape, we remain focused on delivering high-quality healthcare solutions that cater to the diverse needs of our customers."

In FY25, we achieved several key milestones that underscore our dedication to innovation and excellence. Notably, we launched the FREOSSI Large Animals brand, introducing targeted products like Freossi Tone+ and Freossi Power, designed to address health challenges in livestock. Additionally, our Freossi pet care division made its international debut in Sri Lanka, offering nine premium-quality products and a pipeline of over 20 more. We also secured a significant tender from the Tamil Nadu Medical Services Corporation for generic medicines, valued between Rs. 150 million and Rs. 180 million, reinforcing our commitment to affordable healthcare. Furthermore, we are establishing capabilities to produce functional foods for pets, and have launched FREDNA VET DIAGNOSTICS, India's first advanced diagnostic centre exclusively for pets. A notable addition to our product line is the Chuu Balm, which has received an excellent response since its launch, particularly in tier 2 and tier 3 markets.

Looking ahead, our main emphasis will be on expanding our Non-Pharma business, which we believe will serve as a crucial driver of profitability in the years to come. We anticipate strong margin growth in the future due to the introduction of new-age products. We are confident that these initiatives will contribute to our overall growth and profitability, positioning Fredun Pharmaceuticals for a successful future."

About Fredun Pharmaceuticals Limited:

Fredun Pharmaceuticals Limited, healthcare and pharmaceuticals company offer a range of products, including antihypertensives, antidiabetic, antiretroviral drugs (ARVs) and narcotics. It is also engaged in the manufacturing of dietary/herbal supplements, nutraceuticals, cosmeceuticals, and other healthcare products along with animal healthcare products. With such a diverse range of products, the Company's objective is to be a holistic healthcare provider. The Company primarily exports its products to Africa, Southeast Asia, Commonwealth of Independent States (CIS) countries and Latin America.

For more information, please contact:

Fredun Pharmaceuticals Limited

Fredun Medhora

investing@fredungroup.com

Ernst & Young LLP

Abhishek Bhatt

Abhishek.Bhatt3@in.ey.com

DISCLAIMER:

Certain statements in this document that are not historical facts are forward-looking statements. Such forward-looking statements are subject to certain risks and uncertainties like government actions, local, political, or economic developments, industry risks, and many other factors that could cause actual results to differ materially from those contemplated by the relevant forward-looking statements. Fredun Pharmaceuticals Limited will not be responsible for any action taken based on such statements and undertakes no obligation to publicly update these forward-looking statements to reflect subsequent events or circumstances.
